Al Ain Centre, Dubai, United Arab Emirates.
Diabetes Metab Syndr Obes. 2013 Apr 9;6:141-50. doi: 10.2147/DMSO.S36012. Print 2013.
The prevalence of type 2 diabetes is increasing dramatically in the Middle East and North Africa region. However, there are few trials that have determined the effect of antidiabetic treatment in an observational setting in these countries.
This was a noninterventional study performed in Morocco in 2006-2007 and in the Middle East in 2005-2006 to observe the efficacy and safety of acarbose in patients with pretreated or untreated type 2 diabetes. Glycemic parameters (fasting blood glucose, one-hour postprandial blood glucose, and HbA1c) were recorded within a 3-month period. The observation period included an initial visit at the start of acarbose therapy and up to three follow-ups.
Acarbose was effective in reducing glycemic parameters in patients from Morocco (n = 1082) and the Middle East (n = 1737). The mean one-hour postprandial blood glucose decreased by 35.5% to 165.4 ± 47.9 mg/dL in the Middle East and by 35.5% to 179.0 ± 49.9 mg/dL in Morocco. Mean fasting blood glucose decreased by 30.8% to 126.6 ± 34.2 mg/dL (Middle East) and by 34.5% to 150.6 ± 47.1 mg/dL (Morocco). The absolute reduction in HbA1c was 1.3% in the Middle East (final value 7.4%) and 1.0% in Morocco (final value 7.5%). Overall, 107 patients (Middle East) and 26 patients (Morocco) experienced minor drug-related adverse events, which were mainly gastrointestinal. The tolerability of acarbose was rated as very good/good by 80.8% in the Middle East and by 68.6% in Morocco.
This study illustrates the efficacy and safety of acarbose in the treatment of type 2 diabetic patients in an observational setting.
2 型糖尿病在中东和北非地区的患病率正在急剧上升。然而，在这些国家，很少有试验确定了在观察性环境下抗糖尿病治疗的效果。
这是一项非干预性研究，于 2006-2007 年在摩洛哥进行，于 2005-2006 年在中东进行，旨在观察阿卡波糖在预处理或未治疗的 2 型糖尿病患者中的疗效和安全性。在 3 个月的时间内记录血糖参数（空腹血糖、餐后 1 小时血糖和 HbA1c）。观察期包括阿卡波糖治疗开始时的初始就诊和最多 3 次随访。
阿卡波糖在来自摩洛哥（n = 1082）和中东（n = 1737）的患者中有效降低了血糖参数。中东的餐后 1 小时血糖平均降低了 35.5%，降至 165.4 ± 47.9mg/dL；摩洛哥的餐后 1 小时血糖平均降低了 35.5%，降至 179.0 ± 49.9mg/dL。空腹血糖平均降低了 30.8%，降至 126.6 ± 34.2mg/dL（中东）和 34.5%，降至 150.6 ± 47.1mg/dL（摩洛哥）。HbA1c 的绝对降低量为 1.3%（中东的最终值为 7.4%）和 1.0%（摩洛哥的最终值为 7.5%）。总体而言，107 例（中东）和 26 例（摩洛哥）患者出现轻微的药物相关不良反应，主要为胃肠道反应。阿卡波糖的耐受性在中东被评为非常好/好，占 80.8%；在摩洛哥被评为非常好/好，占 68.6%。
本研究表明阿卡波糖在观察性环境下治疗 2 型糖尿病患者的疗效和安全性。
